The International Consortium for Health Outcomes Measurement (ICHOM), an independent non-profit organisation with offices in Cambridge, Massachusetts and London, England, has named physician-entrepreneur Dr Neil Bacon as its new president and CEO, effective immediately, it is reported today.
Dr Bacon succeeds Dr Christina Akerman, who has returned to her native Sweden after four years as president. Dr Bacon, a nephrologist trained at Oxford and Harvard, is a distinguished academic clinician and health information technology entrepreneur. He is internationally recognised leader in quality measurement and engaging patients in their health. Dr Bacon founded Doctors.net.uk in 1996. In recognition of his contributions utilising the Internet to improve healthcare, he was named a Fellow of the Royal College of Physicians in London in 2015. In 2008, Dr Bacon founded iWantGreatCare, an independent organisation enabling patients to rate and review their doctors, dentists, hospitals, after-care facilities, and medications where he was CEO. With reviews from more than five million patients in 23 countries, iWantGreatCare has become a powerful tool for driving health care improvement worldwide.
Harvard Business School professor Michael Porter, ICHOM co-founder and chairman of the board, said, 'Dr Neil Bacon is a pioneer and entrepreneur in use of information technology to enhance quality measurement and change health care. Universal measurement of outcomes that matter to patients, medical condition by medical condition, is the most powerful single tool to change health care.'
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer